Strategic Growth MIRA miniaturized robotic-assisted surgery platform with FDA De Novo clearance presents an opportunity to upsell integration services, instrumentation partnerships, and training programs to hospitals expanding RAS capabilities.

Market Expansion Investments from Cultivate MD and partnerships with Endoscopy Devices signal momentum in the RAS market; target mid to large surgery centers and regional health systems seeking to modernize operating rooms with accessible robotic solutions.

Technology Advantage Extensive IP portfolio and focus on simplifying RAS can be leveraged to position as a preferred platform for OR outsourcing, maintenance contracts, and software updates that enhance procedural efficiency and outcomes.

Leadership & Funding Recent CEO appointment and substantial funding indicate a growth trajectory; align enterprise sales to procurements, long-term service agreements, and strategic collaborations with larger medical device players.

Recognition & Outreach Governor’s Bioscience Award and active conference participation (SAGES) provide credibility and talking points for customer engagement, enabling targeted outreach to academic medical centers and teaching hospitals.